Ensysce Biosciences, Inc. (ENSC)
Develops safer prescription painkillers that release only under specific body conditions to prevent overdose and abuse.
$0.25-0.05%Healthcare
StockGlow Score
Bearish
BearishBullish
1 year ago-87.9%
The outlook
ENSC is trading near its 52-week low, well below both its 50- and 200-day moving averages, signaling a sustained downtrend. Analyst coverage is extremely thin relative to the dramatic price target gap, which shows an average target roughly 65× higher than the current price—a stark disconnect that likely reflects minimal consensus. The overall sentiment leans bearish.
What’s behind the score
Price trendBelow its 50- & 200-day averages
52-week range1% of the way from its 52-week low to high
Price targetAvg target +6528% vs current price
Market cap
$3.8M
52-wk high
$2.75
52-wk low
$0.23
50-day avg
$0.28
200-day avg
$0.86
Trailing P/E
—